MedTrace Logo

Verapamil and Catamenial Epilepsy

NCT00559169 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-04-08

No results posted yet for this study

Summary

One in 3 epilepsy patients have refractory seizures. This drug resistance is likely related to the over expression of multidrug resistance proteins (MDR). Progesterone is a known inhibitor of MDRs and the low level of this hormone during the menstrual cycle may exacerbate seizures, perhaps explaining catamenial epilepsy; i.e. seizures occurring during the menstrual cycle. Verapamil suppresses seizures in animal models of epilepsy perhaps by inhibiting MDRs and thus may help patients with refractory seizures. If the study shows improved seizure control, the results will help establish the role of MDRs in refractory epilepsy.

Conditions

  • Catamenial Epilepsy

Interventions

DRUG

verapamil hyrochloride

80 mg daily by mouth, 5 days prior to menses for 3 months

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Danielle Andrade, MD · College of Physicians and Surgeons of Ontario

Study Design

Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Completion
2010-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00559169 on ClinicalTrials.gov